Skip to Content

Clinical Trial Details

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects with Er, PgR, and Her2 Negative (Triple Negative) Metastatic Breast Cancer - “tnAcity”


The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. Read More >>

IRB Protocol Number
Barbara Beauchemin, RN, BSN at 603-224-2556